Scienture Holdings, Inc. (FRA:4E4)
Germany · Delayed Price · Currency is EUR | Market Cap | 13.54M -20.4% |
| Revenue (ttm) | 718.90K +540.6% |
| Net Income | -33.22M |
| EPS | -1.14 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.1806 |
| Previous Close | 0.2044 |
| Day's Range | 0.1806 - 0.1806 |
| 52-Week Range | 0.0248 - 1.9000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
About Scienture Holdings
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It al... [Read more]
News
DataMeds AI Reports Second Quarter 2026 Financials and Provides Business Update
Revenues grew 14% reaching $1.779M in Q2/26, beating management projections Corporate name change from Wellgistics Health, Inc. to DataMeds AI, Inc. in July 2026, which led to stock symbol change from...
Scienture announces commercial launch of Rezenopy Nasal Spray
Scienture (SCNX) announced the commercial launch of Rezenopy Nasal Spray 10 mg, including the fulfillment of its first purchase orders to U.S. pharmaceutical wholesalers.
DataMEDS AI Announces Its Board of Directors Approved September 9, 2026 as the Payment Date of the Previously Announced Distribution of Dream Bowl Meme Coin I Tokens to Record Holders of Common Stock and other Eligible Equity Securities as of the Record Date of August 7, 2026
TAMPA, FL / ACCESS Newswire / August 14, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMEDS AI," "DataMEDS," or the "Company"), an integrated healthcare company leveraging its Health IT infrastructure ...
SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing Commercial Revenue Base Q2 2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million Q2...
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray
Commercial launch supported by a dedicated national sales force, payer and institutional access, and multi-channel marketing campaign supporting adoption of REZENOPY ™
DataMeds AI Provides Update on Corexa Health's Pharmacy Division
GLP-1 agonist drugs now available Integration of online store CorexaRx.com into Health Lives Here app now complete Medical foods Forzet™ & Galectovid™, and dietary supplement Tollovid® now available R...
DataMeds AI Renames Pharmacy Subsidiaries Corexa Pharmacy and Corexa Tech & Hub Under New Corexa Health Division
TAMPA, FL / ACCESS Newswire / August 10, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a Health IT company leveraging its artificial intelligence platform Einst...
DataMeds AI Reiterates 50:1 Dream Bowl Meme Coin Token to Common Shares Dividend Ratio with an August 7, 2026 Record Date
TAMPA, FL / ACCESS Newswire / August 6, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a Health IT company leveraging its artificial intelligence platform Einste...
DataMeds AI to be Featured In-Person on Fox Business' Claman Countdown to Introduce "Health Lives Here"
Initiative with NFL Alumni Health is aimed at improving rural healthcare access by powering Health Lives Here consumer app that integrates Einstein AI with independent pharmacies and proprietary patie...
DataMeds AI's Corexa Pharmacy Launches Tollo Health's Tollovid(R) and Galactovid(TM)
Launch targets acute viral infection and Long COVID markets through www.CorexaRx.com/Store TAMPA, FL / ACCESS Newswire / July 31, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI" or the "Company"...
DataMeds AI Expands License with DataVault AI for Data Driven Outcome Healthcare-focused Blockchain and Data Monetization License
Data monetization and real-world asset tokenization technologies licensed into the DataMeds AI's EinsteinRX Platform Healthcare data represents 30%+ of global data assets growing by 36% per annum; DVL...
Datavault AI Expands Data Driven Outcome Healthcare-focused Blockchain and Data Monetization License With DataMeds AI
PHILADELPHIA--(BUSINESS WIRE)---- $DVLT #DatavaultAI--Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ: DVLT), a provider of data monetization, credentialing, digital engagement, and real-w...
DataMEDS AI Announces Updated August 7, 2026 Record Date for Distribution of Dream Bowl 2026 Meme Coin to Stockholders
TAMPA, FL / ACCESS Newswire / July 27, 2026 / DataMEDS AI, Inc., (NASDAQ:MEDS, "DataMEDS," or the "Company"), a health information technology leader implementing EinsteinRx™ artificial intelligence pr...
DataMEDS AI Officially Begins Trading Under Stock Symbol 'MEDS' on the NASDAQ Capital Markets
Trading under new symbol (NASDAQ: MEDS) completes corporate rebranding from prior corporate name Wellgistics Health (NASDAQ: WGRX) TAMPA, FL / ACCESS Newswire / July 22, 2026 / DataMEDS AI, Inc., (NAS...
Scienture to begin shipments of Rezonopy to wholesalers
Scienture (SCNX) announced that it has completed manufacturing of commercial launch inventory and will begin shipments later this month of Rezonopy Nasal Spray 10 mg to U.S. pharmaceutical wholesalers...
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
Commercial availability expected in August as the Company advances the rollout of the highest-dose FDA-approved naloxone hydrochloride nasal spray
Scienture announces progress in commercialization of Arbli
Scienture (SCNX) announced significant progress in the commercialization of Arbli, including expanded payor coverage, broader pharmacy access, new channel partnerships, and ongoing initiatives designe...
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
Broader pharmacy access, channel expansion, and payer coverage position Arbli ™ for increased prescription volume and revenue growth
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
Commercial Launch Planned for Mid-July; 5,000+ Healthcare Facilities Reached Through GPO Agreements, Covering ~60% of Institutional GPO Market
SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC
COMMACK, NY / ACCESS Newswire / June 4, 2026 / SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value...
Scienture reveives U.S. patent covering Rezenopy Nasal Spray
Scienture (SCNX) announced that the United States Patent and Trademark Office has granted U.S. Patent No. 12,622,903 B2, patent covering Rezenopy Nasal Spray 10 mg, effective May 12, with an…
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
U.S. Naloxone Market: ~$141 million in annual sales and 9.4 million units annually COMMACK, NY, June 02, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existin...
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
COMMACK, NY, May 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing ...
Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
Proceeds support commercialization of Arbli ™ , the first FDA-approved ready-to-use oral suspension for hypertension; and REZENOPY ™ , life-saving opioid overdose emergency treatment
Scienture announces third patent granted for Arbli
Scienture (SCNX) announced that the United States Patent and Trademark Office has granted its third patent covering Arbli oral suspension, the first and only FDA-approved ready-to-use oral liquid form...